Save
Email
Print
ShareSep. 12, 2012 — A study coordinated by Manel Esteller, published in Nature Reviews Genetics, highlights the success of epigenetics to predict the behavior and weaknesses of tumors.
The research team led by Manel Esteller, director of the Cancer Epigenetics and Biology Program at the Bellvitge Biomedical Research Institute (IDIBELL), professor of genetics at the University of Barcelona and ICREA researcher, has updated the latest findings in applied epigenetic in a review paper published in Nature Reviews Genetics.
There is a growing need for better biomarkers that allow early detection of human diseases, especially cancer. The markers can improve primary prevention, diagnosis and prognosis of disease. Furthermore, it is possible to predict which may be more effective treatments according to patient characteristics, which is known by the name of personalized medicine.
The genetic tests complementary to traditional methods have been used to improve the approach to various diseases, but in the last ten years epigenetics has hardly emerged to help solve these clinical situations, as highlighted by the article. Epigenetics is the discipline for the study of the chemical changes in our genetic material and the same regulatory proteins. The most known epigenetic mark is the addition of a methyl group to the DNA.
The paper notes that the last decade two tests based on the methylation of two genes, MGMT and GSTP1, have been proved vital in predicting brain tumors sensitive to the temozolomide drug and in distinguishing prostate cancer compared benign growth, respectively. Dr. Esteller points out that "the most exciting thing is that they are currently being identified new epigenetic biomarkers for predicting the performance and weaknesses of tumors at a fast pace." In this sense, the coordinator of the study cites the recent identification of epigenetic alterations in predictive genes as response to new generation drugs in leukemia and the fact that obtaining a "picture" of the DNA methylation pattern can expose unknown tumors that previously had a very poor prognosis.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by IDIBELL-Bellvitge Biomedical Research Institute.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Holger Heyn, Manel Esteller. DNA methylation profiling in the clinic: applications and challenges. Nature Reviews Genetics, 2012; DOI: 10.1038/nrg3270
Note: If no author is given, the source is cited instead.
more 
